Previous 10 | Next 10 |
The shares of BridgeBio Pharma (NASDAQ:BBIO) traded higher in the morning hours Wednesday after the clinical-stage biotech announced encouraging data from the first two subjects who received the company’s Canavan disease candidate BP-812 in a Phase 1/2 clinical trial. An ultra-rare and...
- These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with the severity of disease - Initial pharmacodynamic results for two participants show unprecedented decreases in N-acetylaspartate (NAA) in the brain a...
Gainers: Novavax (NVAX) +259%. Precision BioSciences (DTIL) +114%. Amazon.com (AMZN) +39%. Adobe (ADBE) +32%. Paratek Pharmaceuticals (PRTK) +15%. Losers:Euronet Worldwide (EEFT) -5%. Seres Therapeutics (MCRB) -5%. Sanderson Farms (SAFM) -5%. Morphic Holding (MORF) -4%. Redbox Entertainm...
Stephen Bardin will join as CFO Designate on June 27, 2022 After a transition period, atai’s current CFO Greg Weaver will be moving into a part time strategic advisory role NEW YORK and BERLIN, June 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V., (Nasdaq: ATAI) (...
BridgeBio Pharma's (NASDAQ:BBIO) phase 2 trial for the low calcium disorder autosomal dominant hypocalcemia type 1 showed that patients treated with encaleret saw improvements in calcium levels through 24 weeks. At week 24 of treatment, 92% of participants had normal trough blood calcium leve...
- Treatment with encaleret resulted in rapid and sustained restoration of normal mineral homeostasis, with mean values of blood calcium, urinary calcium, and blood PTH within the normal range by day 5 of therapy and sustained at 24 weeks, and was well-tolerated without any reported seriou...
PALO ALTO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and its affiliate company Venthera, Inc. (Venthera), today announced preliminary data from the Phase 1b trial of VT30 topical gel (BBP-681) in patients with venous, lymphatic and mixed ven...
BBIO lost hugely after the December phase 3 flop. So, although its business model is very interesting, it is not de-risked. It does have a lot of cash. For further details see: BridgeBio Pharma: Yet To Be Proven Business Model
- BridgeBio will host an investor call on June 13, 2022, at 4:30 pm ET to discuss the Phase 2b study results and the planned pivotal Phase 3 study design PALO ALTO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the ...
PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team wi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...